top of page


Embracing the potential of this transformative drug treatment while addressing possible challenges



Specificity in its Mechanism

Because Lykosa can differentiate between cancerous and healthy cells through MUC-1 targeting, Lykosa is more effective than traditional methods such as chemotherapy and radiation therapy. This has the potential to reduce side effects and the probability of relapse.

Screen Shot 2021-04-06 at 2.15.49 PM.png
Screen Shot 2021-04-01 at 4.08.07 PM.png

Safer Alternative


Lykosa is a safer alternative than other treatments, as it minimizes the risk typically associated with surgery such as infection and human error. Additionally, this technology employs biomimetic cell death mechanisms, found in the body’s own natural killer white blood cells.





Lykosa may lead to immunosuppression and increased risk of infection. The potential for immunosuppression exists if Lykosa saturates macrophage capacity preventing macrophage activation of T cells. A second area of potential concern is liposomal accumulation in the liver. However, current research suggests that under certain circumstances, PEG can detach from the liposome, allowing for the reticuloendothelial system to dispose of Lykosa.

Screen Shot 2021-03-29 at 8.06.35 PM.png
Screen Shot 2021-03-29 at 8.10.58 PM.png

Compromised Targeting

A small percentage of liposomes may experience compromised targeting due to external factors which may affect the efficacy of this therapy.  In addition, due to biological processes of the body, Lykosa may be metabolized differently, depending on the patient. However, this is to be expected by all medicines or drugs that are injected into the human body.

logo_white_background copy.png
bottom of page